InvestorWire NewsRoom

InvestorNewsBreak

InvestorNewsBreaks – uniQure N.V. (NASDAQ: QURE) Featured in Mizuho Securities Research Report
December 14, 2021

InvestorNewsBreaks – uniQure N.V. (NASDAQ: QURE) Featured in Mizuho Securities Research Report

uniQure (NASDAQ: QURE) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “We spoke with uniQure following our recent assumption of coverage of the company’s stock and ahead of the upcoming, highly anticipated initial data readout from AMT-130 Phase I/II trial in four Huntington’s disease patients, expected by YE21. We believe investor expectations are very low and see a favorable risk/reward for the stock going into this data. That said, we remain cautious given the small sample size and limited follow-up on the biomarker data which could make it hard for investors to gain greater conviction in AMT-130 at this point. We provide our thoughts below.”

To request access to the full report, visit https://ibn.fm/MECiY

About uniQure N.V.

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The company is leveraging its modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington’s disease, Fabry disease, spinocerebellar ataxia Type 3 temporal lobe epilepsy, Alzheimer’s, Parkinson’s and ALS. For more information, visit the company’s website at www.uniQure.com.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Recent NewsBreaks

NewsBreaks Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).